Free Trial

Century Therapeutics (IPSC) Competitors

Century Therapeutics logo
$0.56 +0.02 (+4.19%)
As of 02:26 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

IPSC vs. CHRS, BIOA, GNLX, CRBP, FBRX, DERM, FATE, PLX, IPHA, and TNXP

Should you be buying Century Therapeutics stock or one of its competitors? The main competitors of Century Therapeutics include Coherus Oncology (CHRS), BioAge Labs (BIOA), Genelux (GNLX), Corbus Pharmaceuticals (CRBP), Forte Biosciences (FBRX), Journey Medical (DERM), Fate Therapeutics (FATE), Protalix BioTherapeutics (PLX), Innate Pharma (IPHA), and Tonix Pharmaceuticals (TNXP). These companies are all part of the "pharmaceutical products" industry.

Century Therapeutics vs. Its Competitors

Century Therapeutics (NASDAQ:IPSC) and Coherus Oncology (NASDAQ:CHRS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability.

Coherus Oncology has higher revenue and earnings than Century Therapeutics. Century Therapeutics is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Century Therapeutics$6.59M7.41-$126.57M-$0.29-1.95
Coherus Oncology$266.96M0.76$28.51M$1.551.13

Century Therapeutics has a beta of 1.78, indicating that its stock price is 78% more volatile than the S&P 500. Comparatively, Coherus Oncology has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500.

Century Therapeutics currently has a consensus target price of $3.75, suggesting a potential upside of 563.72%. Coherus Oncology has a consensus target price of $4.51, suggesting a potential upside of 157.12%. Given Century Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Century Therapeutics is more favorable than Coherus Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Century Therapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Coherus Oncology
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

50.2% of Century Therapeutics shares are owned by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are owned by institutional investors. 5.0% of Century Therapeutics shares are owned by insiders. Comparatively, 8.1% of Coherus Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Coherus Oncology has a net margin of 125.90% compared to Century Therapeutics' net margin of -19.10%. Coherus Oncology's return on equity of 0.00% beat Century Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Century Therapeutics-19.10% -11.53% -6.94%
Coherus Oncology 125.90%N/A -34.85%

In the previous week, Century Therapeutics had 2 more articles in the media than Coherus Oncology. MarketBeat recorded 3 mentions for Century Therapeutics and 1 mentions for Coherus Oncology. Coherus Oncology's average media sentiment score of 0.67 beat Century Therapeutics' score of 0.19 indicating that Coherus Oncology is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Century Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Coherus Oncology
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Coherus Oncology beats Century Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Century Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for IPSC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IPSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IPSC vs. The Competition

MetricCentury TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$48.81M$2.64B$6.17B$10.69B
Dividend YieldN/A57.79%5.72%4.83%
P/E Ratio-1.9523.8029.4327.35
Price / Sales7.41803.84589.84133.82
Price / CashN/A27.2425.8230.35
Price / Book0.305.4712.466.69
Net Income-$126.57M$33.06M$3.32B$276.36M
7 Day Performance2.75%1.53%2.28%0.88%
1 Month Performance18.40%9.91%8.61%3.83%
1 Year Performance-64.69%-2.89%61.86%36.51%

Century Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IPSC
Century Therapeutics
2.7731 of 5 stars
$0.57
+4.2%
$3.75
+563.7%
-66.1%$48.81M$6.59M-1.95170News Coverage
Analyst Downgrade
CHRS
Coherus Oncology
4.1733 of 5 stars
$1.73
+3.6%
$4.51
+160.8%
+86.9%$194.10M$266.96M1.12330
BIOA
BioAge Labs
N/A$5.50
+2.8%
N/AN/A$191.80MN/A0.00N/A
GNLX
Genelux
0.8552 of 5 stars
$5.25
+3.6%
$20.33
+287.3%
+108.0%$191.51M$10K-6.1010Gap Up
CRBP
Corbus Pharmaceuticals
4.2245 of 5 stars
$16.32
+5.0%
$45.43
+178.4%
+4.9%$190.45MN/A-3.4340News Coverage
Analyst Forecast
Gap Up
FBRX
Forte Biosciences
2.7975 of 5 stars
$14.75
-3.4%
$68.00
+361.0%
+155.4%$189.85MN/A-0.915Analyst Downgrade
Short Interest ↑
DERM
Journey Medical
2.0188 of 5 stars
$7.00
-2.9%
$12.17
+73.8%
+17.6%$189.69M$56.13M-18.4290
FATE
Fate Therapeutics
4.1224 of 5 stars
$1.39
-15.0%
$3.30
+137.4%
-54.5%$188.56M$13.63M-0.96550Gap Up
PLX
Protalix BioTherapeutics
2.1118 of 5 stars
$2.45
+3.8%
$15.00
+512.2%
+70.6%$188.17M$61.95M-18.85200
IPHA
Innate Pharma
2.1002 of 5 stars
$1.93
-4.9%
$6.50
+236.8%
+6.4%$187.13M$21.77M0.00220
TNXP
Tonix Pharmaceuticals
2.8077 of 5 stars
$20.06
-5.3%
$70.00
+249.0%
+3.4%$185.75M$10.09M-0.5150Short Interest ↑
Gap Down

Related Companies and Tools


This page (NASDAQ:IPSC) was last updated on 10/20/2025 by MarketBeat.com Staff
From Our Partners